Both National Comprehensive Cancer Network (NCCN) Guidelines for Hepatobiliary Cancers and Guidelines for Diagnosis and Treatment of Primary Liver Cancer recommend PD-1/L1 inhibitors as first-line drugs for systemic treatment of HCC (Du et al., 2022; Llovet et al., 2022). Here, PDCD1 is linked to liver cancer.